dipyridamole has been researched along with B-Cell Lymphoma in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Motoyama, O | 1 |
| Kojima, Y | 1 |
| Ohara, A | 1 |
| Tsukimoto, I | 1 |
| Ishikawa, Y | 1 |
| Iitaka, K | 1 |
1 other study available for dipyridamole and B-Cell Lymphoma
| Article | Year |
|---|---|
IgA nephropathy associated with leukemia and lymphoma: report of two cases.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Di | 2008 |